Enovis Corp ENOV
We take great care to ensure that the data presented and summarized in this overview for Enovis CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENOV
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.63MShares$281 Million0.17% of portfolio
-
Black Rock Inc. New York, NY5.43MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$229 Million0.0% of portfolio
-
Diamond Hill Capital Management Inc Columbus, OH3MShares$127 Million0.54% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.99MShares$126 Million0.03% of portfolio
-
Davenport & CO LLC2.63MShares$111 Million0.67% of portfolio
-
Royce & Associates LP2.4MShares$102 Million0.98% of portfolio
-
American Century Companies Inc Kansas City, MO2.33MShares$98.6 Million0.06% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$79.6 Million0.04% of portfolio
-
State Street Corp Boston, MA1.65MShares$69.7 Million0.0% of portfolio
Latest Institutional Activity in ENOV
Top Purchases
Top Sells
About ENOV
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Insider Transactions at ENOV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
523
+4.13%
|
-
|
Aug 05
2024
|
Louis Vogt GROUP PRESIDENT, RECON |
SELL
Payment of exercise price or tax liability
|
Direct |
285
-1.17%
|
$11,685
$41.69 P/Share
|
Aug 05
2024
|
Terry D Ross GROUP PRESIDENT, P&R |
SELL
Payment of exercise price or tax liability
|
Direct |
325
-1.63%
|
$13,325
$41.69 P/Share
|
Aug 05
2024
|
John Kleckner Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
164
-2.47%
|
$6,724
$41.69 P/Share
|
Jul 19
2024
|
John Kleckner Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
65
-0.97%
|
$2,990
$46.71 P/Share
|
Jun 28
2024
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
498
+4.11%
|
-
|
Jun 03
2024
|
Phillip Benjamin (Ben) Berry SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
627
-1.75%
|
$31,350
$50.27 P/Share
|
May 20
2024
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+28.07%
|
-
|
May 20
2024
|
A Clayton Perfall |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+10.19%
|
-
|
May 20
2024
|
Rajiv Vinnakota |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+16.68%
|
-
|
May 20
2024
|
Barbara W. Bodem |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+34.44%
|
-
|
May 20
2024
|
Christine Ortiz |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+34.44%
|
-
|
May 20
2024
|
Sharon L Wienbar |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+14.3%
|
-
|
May 20
2024
|
Philip Okala |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+34.44%
|
-
|
May 20
2024
|
Liam Kelly |
BUY
Grant, award, or other acquisition
|
Direct |
4,338
+25.01%
|
-
|
Mar 28
2024
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
361
+5.06%
|
-
|
Mar 06
2024
|
Brady Shirley Pres. & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,023
-2.17%
|
$123,403
$61.84 P/Share
|
Mar 06
2024
|
Daniel A Pryor EVP, Strategy & Business Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,728
-1.34%
|
$105,408
$61.84 P/Share
|
Mar 06
2024
|
Bradley J Tandy SVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
777
-2.97%
|
$47,397
$61.84 P/Share
|
Mar 06
2024
|
Matthew L. Trerotola CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,157
-2.23%
|
$375,577
$61.84 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 280K shares |
---|
Payment of exercise price or tax liability | 75.6K shares |
---|